Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
NarcolepsyExcessive Daytime SleepinessCataplexy Narcolepsy
Interventions
DRUG

mazindol extended release

Dosed orally, once daily for up to 3 weeks

DRUG

Placebo

Dosed orally, once daily for up to 4 weeks.

Trial Locations (22)

20815

The Center For Sleep & Wake Disorders, Chevy Chase

27534

Superior Clinical Research, LLC, Goldsboro

28025

Carolinas Sleep Specialists, Concord

28078

Advanced Respiratory and Sleep Medicine, Huntersville

29201

Bogan Sleep Consultants, Columbia

30281

Clinical Research Institute, Stockbridge

30315

Treken Primary care, Atlanta

30328

NeuroTrials Research, Atlanta

33016

The Angel Medical Research Corporation, Miami Lakes

33126

Sleep Medicine Specialists of South Florida, Miami

33155

Ivetmar Medical Group, Miami

33765

St. Francis Sleep Allergy and Lung Institute, Clearwater

35213

Sleep Disorders Center of Alabama, Birmingham

43017

Ohio Sleep Medicine Institute, Dublin

45245

Intrepid Research, Cincinnati

48314

Sleep and Attention Disorders, Sterling Heights

65212

Neurology and Sleep Disorders Clinic, Columbia

75235

Dharma PA d/b/a Southwest Family Medicine Associates, Dallas

78229

Sleep Therapy & Research Center, San Antonio

92103

Pacific Research Network, San Diego

94063

Stanford Sleep Medicine Center, Redwood City

96817

Hawaii Pacific Neuroscience Clinical Research Center, Honolulu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NLS Pharmaceutics

INDUSTRY